Insights & Resources

Discover how outsourcing in pharmaceutical manufacturing enhances quality, ensures compliance and mitigates risks in a rapidly evolving industry.

Learn how HMRC's guidelines impact transfer pricing for life sciences and other multinationals and how to mitigate risks and ensure compliance.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

By adopting best practices for fraud prevention and fostering a culture of transparency, NFPs can safeguard their resources and continue to make a positive impact.

Unravel life sciences industry complexities, and discover the differences between FDA special review designations like Fast Track, Priority Review and Breakthrough.

The credit is aimed at bolstering and incentivizing the emerging biotechnology sector to create jobs and invest in NYC and is available 1/1/23-1/1/26.

Change Healthcare was impacted by a cybersecurity incident that breached its information technology network.

In a business sale, due diligence is critical to mitigate the risk of unexpected tax issues for buyers and sellers. Find out key components of tax due diligence.

A summary of changes to R&E expenditure tax treatment in the proposed Tax Relief for American Families and Workers Act of 2024.